Canada markets close in 2 hours 7 minutes

Exagen Inc. (XGN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4149+0.0349 (+2.53%)
As of 01:32PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.3800
Open1.3800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.3600 - 1.4149
52 Week Range1.3000 - 3.9230
Volume10,089
Avg. Volume32,888
Market Cap24.558M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.3400
Earnings DateMay 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
  • GlobeNewswire

    Exagen Announces Campaign for Lupus Awareness Month

    CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE). Lupus Awareness Month occurs every May and is an important platform for lupus-focused organizations to educate and advoc

  • GlobeNewswire

    Exagen to Announce First Quarter 2024 Results on May 13, 2024

    CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing (201) 38

  • GlobeNewswire

    Exagen Inc. Announces Changes to the Board of Directors

    CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the